Literature DB >> 6707876

High-performance liquid chromatographic analysis of the semisynthetic epipodophyllotoxins teniposide and etoposide using electrochemical detection.

J A Sinkule, W E Evans.   

Abstract

A high-performance liquid chromatographic (HPLC) assay was developed for the quantitation of two structurally similar and highly active anticancer drugs, etoposide (I) and teniposide (II), and their potential metabolites (hydroxy acid, picrolactone, and aglycone). The assay utilizes electrochemical detection, which imparts specificity and sensitivity sufficient to detect greater than or equal to 20 ng/mL in plasma, urine, and CSF. The mean assay coefficients of variation were 5.1 and 8.1% for teniposide (10 micrograms/mL) and etoposide (5 micrograms/mL), respectively. The extraction efficiencies were 86% for etoposide, 70% for its hydroxy acid metabolite, 66% for teniposide, and 54% for the hydroxy acid of teniposide. The correlation coefficient of the multilevel standard curve was greater than or equal to 0.995 over the concentration range of 0.05-50 micrograms/mL for the parent drugs and metabolites extracted from plasma. This method has been used to determine the concentrations of the parent drugs and their metabolites in the plasma, urine, and CSF of patients with cancer.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6707876     DOI: 10.1002/jps.2600730207

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  11 in total

Review 1.  Etoposide and teniposide. Bioanalysis, metabolism and clinical pharmacokinetics.

Authors:  J J Holthuis
Journal:  Pharm Weekbl Sci       Date:  1988-06-17

2.  Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study.

Authors:  G Freyer; B Tranchand; B Ligneau; C Ardiet; P J Souquet; I Court-Fortune; R Riou; P Rebattu; J P Boissel; V Trillet-Lenoir; P Girard
Journal:  Br J Clin Pharmacol       Date:  2000-10       Impact factor: 4.335

3.  Disposition of total and unbound etoposide following high-dose therapy.

Authors:  T L Schwinghammer; R A Fleming; C S Rosenfeld; D Przepiorka; R K Shadduck; E J Bloom; C F Stewart
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  Somnolence, hypotension, and metabolic acidosis following high-dose teniposide treatment in children with leukemia.

Authors:  H L McLeod; D K Baker; C H Pui; J H Rodman
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 5.  The clinical pharmacology of etoposide and teniposide.

Authors:  P I Clark; M L Slevin
Journal:  Clin Pharmacokinet       Date:  1987-04       Impact factor: 6.447

Review 6.  Disposition of antineoplastic agents in the very young child.

Authors:  H L McLeod; M V Relling; W R Crom; K Silverstein; S Groom; J H Rodman; G K Rivera; W M Crist; W E Evans
Journal:  Br J Cancer Suppl       Date:  1992-08

7.  Pharmacokinetics of continuous-infusion amsacrine and teniposide for the treatment of relapsed childhood acute nonlymphocytic leukemia.

Authors:  W P Petros; J H Rodman; J Mirro; W E Evans
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

8.  High-dose ifosfamide, carboplatin, and etoposide pharmacokinetics: correlation of plasma drug levels with renal toxicity.

Authors:  J E Wright; A Elias; O Tretyakov; S Holden; J Andersen; C Wheeler; G Schwartz; K Antman; A Rosowsky; E Frel
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

9.  Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.

Authors:  V M Herben; W W ten Bokkel Huinink; A C Dubbelman; I A Mandjes; Y Groot; D M van Gortel-van Zomeren; J H Beijnen
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells.

Authors:  M K Ritke; D Roberts; W P Allan; J Raymond; V V Bergoltz; J C Yalowich
Journal:  Br J Cancer       Date:  1994-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.